In a murine model, PLX3397 administration significantly increased the number of antigen-presenting macrophages and CD8+ T cells with a simultaneous reduction in MDSCs within tumor tissues, indicating an anti-tumoral shift in the TME [114]. This evidence concerns the gene CD8A and neoplasm.